Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma

被引:46
作者
Manzano, Mark [1 ]
Patil, Ajinkya [1 ]
Waldrop, Alexander [2 ,3 ]
Dave, Sandeep S. [2 ,3 ]
Behdad, Amir [4 ]
Gottwein, Eva [1 ]
机构
[1] Northwestern Univ, Dept Microbiol Immunol, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Duke Univ, Duke Canc Inst, Durham, NC 27708 USA
[3] Duke Univ, Ctr Genom & Computat Biol, Durham, NC 27708 USA
[4] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA
来源
NATURE COMMUNICATIONS | 2018年 / 9卷
关键词
NF-KAPPA-B; CELL-DEATH; DNA-SEQUENCES; IN-VIVO; EXPRESSION PROFILE; NUCLEAR ANTIGEN; BCL-2; PROTEINS; KSHV VFLIP; SARCOMA; APOPTOSIS;
D O I
10.1038/s41467-018-05506-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus. Our understanding of PEL is poor and therefore treatment strategies are lacking. To address this need, we conducted genome-wide CRISPR/Cas9 knockout screens in eight PEL cell lines. Integration with data from unrelated cancers identifies 210 genes as PEL-specific oncogenic dependencies. Genetic requirements of PEL cell lines are largely independent of Epstein-Barr virus co-infection. Genes of the NF-kappa B pathway are individually non-essential. Instead, we demonstrate requirements for IRF4 and MDM2. PEL cell lines depend on cellular cyclin D2 and c-FLIP despite expression of viral homologs. Moreover, PEL cell lines are addicted to high levels of MCL1 expression, which are also evident in PEL tumors. Strong dependencies on cyclin D2 and MCL1 render PEL cell lines highly sensitive to palbociclib and S63845. In summary, this work comprehensively identifies genetic dependencies in PEL cell lines and identifies novel strategies for therapeutic intervention.
引用
收藏
页数:14
相关论文
共 71 条
  • [21] Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
    Gopalakrishnan, R.
    Matta, H.
    Tolani, B.
    Triche, T., Jr.
    Chaudhary, P. M.
    [J]. ONCOGENE, 2016, 35 (14) : 1797 - 1810
  • [22] Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes:: Modulation of interferon-regulated gene expression by Rel/nuclear factor κB
    Grumont, RJ
    Gerondakis, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (08) : 1281 - 1291
  • [23] RETRACTED: KSHV vFLIP is essential for the survival of infected lymphoma cells (Retracted Article)
    Guasparri, I
    Keller, SA
    Cesarman, E
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (07) : 993 - 1003
  • [24] High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities
    Hart, Traver
    Chandrashekhar, Megha
    Aregger, Michael
    Steinhart, Zachary
    Brown, Kevin R.
    MacLeod, Graham
    Mis, Monika
    Zimmermann, Michal
    Fradet-Turcotte, Amelie
    Sun, Song
    Mero, Patricia
    Dirks, Peter
    Sidhu, Sachdev
    Roth, Frederick P.
    Rissland, Olivia S.
    Durocher, Daniel
    Angers, Stephane
    Moffat, Jason
    [J]. CELL, 2015, 163 (06) : 1515 - 1526
  • [25] DNA targeting specificity of RNA-guided Cas9 nucleases
    Hsu, Patrick D.
    Scott, David A.
    Weinstein, Joshua A.
    Ran, F. Ann
    Konermann, Silvana
    Agarwala, Vineeta
    Li, Yinqing
    Fine, Eli J.
    Wu, Xuebing
    Shalem, Ophir
    Cradick, Thomas J.
    Marraffini, Luciano A.
    Bao, Gang
    Zhang, Feng
    [J]. NATURE BIOTECHNOLOGY, 2013, 31 (09) : 827 - +
  • [26] Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a gene expression profile
    Jenner, RG
    Maillard, K
    Cattini, N
    Weiss, RA
    Boshoff, C
    Wooster, R
    Kellam, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) : 10399 - 10404
  • [27] Katano H, 2001, CANCER, V92, P3076, DOI 10.1002/1097-0142(20011215)92:12<3076::AID-CNCR10117>3.0.CO
  • [28] 2-D
  • [29] NF-κB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo
    Keller, SA
    Hernandez-Hopkins, D
    Vider, J
    Ponomarev, V
    Hyjek, E
    Schattner, EJ
    Cesarman, E
    [J]. BLOOD, 2006, 107 (08) : 3295 - 3302
  • [30] Keller SA, 2000, BLOOD, V96, P2537